BiomX Announces Positive Results from Part 1 of the Phase Ib/IIa Study Evaluating BX004 for Treatment of Chronic Pulmonary Infections in Patients with Cystic Fibrosis

BiomX, Inc. announced positive results from Part 1 of the Phase Ib/IIa trial evaluating the Company’s novel phage cocktail, BX004, for the treatment of chronic pulmonary infections caused by Pseudomonas aeruginosa in patients with cystic fibrosis.